dTAGV-1 (35 mg/kg; i.p. once daily for 4 days) TFA induces degradation of FKBP12F36V-Nluc in mice[1].
dTAGV-1 (2-10 mg/kg; i.p.) TFA exhbits half-lives (T1/2=3.64 and 4.4 h), Cmax (595 and 2123 ng/mL) and great exposure (AUCinf=3136 and18517 hng/mL) in mice[1].
dTAGV-1 (2 mg/kg; i.v.) TFA exhbits half-life (T1/2=3.02 h), Cmax (7780 ng/mL) and great exposure (AUCinf=3329 hng/mL) in mice[1].
| Animal Model: | 8-week-old immunocompromised female mice were transplanted with MV4;11 luc-FKBP12F36V cells[1] |
| Dosage: | 35 mg/kg |
| Administration: | I.p. once daily for 4 days |
| Result: | Observed striking loss of bioluminescent signal 4h after the first and three administrations.
Degradation evident 28h after the final administration.
|
